TY - JOUR AU - Zarogoulidis, Konstantinos AU - Zarogoulidis, Paul AU - Darwiche, Kaid AU - Boutsikou, Efimia AU - Machairiotis, Nikolaos AU - Tsakiridis, Kosmas AU - Katsikogiannis, Nikolaos AU - Kougioumtzi, Ioanna AU - Karapantzos, Ilias AU - Huang, Haidong AU - Spyratos, Dionysios PY - 2013 TI - Treatment of non-small cell lung cancer (NSCLC) JF - Journal of Thoracic Disease; Vol 5, Supplement 4 (September 30, 2013): Journal of Thoracic Disease (Lung cancer: an update on current and future diagnostic and treatment techniques) Y2 - 2013 KW - N2 - Radical surgery is the standard of care for fit stage I non-small cell lung cancer (NSCLC) patients. Adjuvant treatment should be offered only as part of an investigation trial. Stage II and IIIA adjuvant cisplatin-based chemotherapy remains the gold standard for completely resected NSCLC tumors. Additionally radiotherapy should be offered in patients with N2 lymph nodes. In advanced stage IIIB/IV or inoperable NSCLC pts, a multidisciplinary treatment should be offered consisted of 4 cycles of cisplatin-based chemotherapy plus a 3 rd generation cytotoxic agent or a cytostatic (anti-EGFR, anti-VEGFR) drug. UR - https://jtd.amegroups.org/article/view/1401